Basic Evaluation of the Newly Developed "Lias Auto P-FDP" Assay and the Influence of Plasmin-α2 Plasmin Inhibitor Complex Values on Discrepancy in the Comparison with "Lias Auto D-Dimer Neo" Assay

Although previous studies have revealed that elevated D-dimer in the early stage of coronavirus 2019 (COVID-19) indicates pulmonary intravascular coagulation, the state of coagulation/fibrinolysis disorder with normal D-dimer is unknown. The study aimed to investigate how coagulation/fibrinolysis markers affect severe respiratory failure in the early stage of COVID-19. Among 1043 patients with COVID-19, 797 patients were included in our single-center retrospective study. These 797 patients were divided into two groups, the normal D-dimer and elevated D-dimer groups and analyzed for each group. A logistic regression model was fitted for age, sex, body mass index (BMI) ≥ 30 kg/m2, fibrinogen ≥ 617 mg/dL, thrombin-antithrombin complex (TAT) ≥ 4.0 ng/mL, and plasmin-alpha2-plasmin inhibitor-complex (PIC) > 0.8 µg/mL. A multivariate analysis of the normal D-dimer group demonstrated that being male and TAT ≥ 4.0 ng/mL significantly affected severe respiratory failure. In a multivariate analysis of the elevated D-dimer group, BMI ≥ 30 kg/m2 and fibrinogen ≥ 617 mg/dL significantly affected severe respiratory failure. The elevated PIC did not affect severe respiratory failure in any group. Our study demonstrated that hypercoagulation due to SARS-CoV-2 infection may occur even during a normal D-dimer level, causing severe respiratory failure in COVID-19.

Download Full-text

Kinetic properties of the primary inhibitor of plasmin from human plasma

Biochemical Journal ◽

10.1042/bj1630389 ◽

1977 ◽

Vol 163 (2) ◽

pp. 389-391 ◽

Cited By ~ 74

Author(s):

U Christensen ◽

I Clemmensen

Keyword(s):

Human Plasma ◽

Enzyme Inhibitor ◽

Kinetic Properties ◽

Inhibitor Complex ◽

Rapid Formation ◽

Plasmin Inhibitor

The interaction of human plasmin with the newly discovered alpha2-plasmin inhibitor was investigated. It was found from rate measurements that the reaction involves the rapid formation of a first enzyme-inhibitor complex, followed by the slow irreversible transition to another complex. L-Lysine influences the first step, but not the second.

Download Full-text

2.P.362 Morning hypercoagulability and hypofibrinolysis: diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor-complex

Atherosclerosis ◽

10.1016/s0021-9150(97)89001-6 ◽

1997 ◽

Vol 134 (1-2) ◽

pp. 192

Author(s):

S. Kapiotis ◽

B. Jilma ◽

P. Quehenberger ◽

K. Ruzicka ◽

S. Handler ◽

...

Keyword(s):

Diurnal Variations ◽

Factor Vii ◽

Prothrombin Fragment ◽

Inhibitor Complex ◽

Activated Factor Vii ◽

Plasmin Inhibitor

Download Full-text

Significance of Elevated Thrombin-Antithrombin III Complex and Plasmin-??2-Plasmin Inhibitor Complex in the Acute Stage of Nontraumatic Subarachnoid Hemorrhage

Neurosurgery ◽

10.1097/00006123-199412000-00006 ◽

1994 ◽

Vol 35 (6) ◽

pp. 1055???1060 ◽

Cited By ~ 1

Author(s):

Youichi Itoyama ◽

Shodo Fujioka ◽

Shuichi Takaki ◽

Motohiro Morioka ◽

Takuichiro Hide ◽

...

Keyword(s):

Subarachnoid Hemorrhage ◽

Antithrombin Iii ◽

Acute Stage ◽

Inhibitor Complex ◽

Thrombin Antithrombin Iii Complex ◽

Plasmin Inhibitor

Download Full-text

Modifications of α2-Plasmin Inhibitor During Treatments by a Defibrinating Agent

10.1055/s-0039-1684848 ◽

1979 ◽

Author(s):

M. Samama ◽

J. Conard ◽

B. Cazenave ◽

A. Derlon ◽

A. Gaudric ◽

...

Keyword(s):

Retinal Vein Occlusion ◽

Antithrombin Iii ◽

Fibrinogen Level ◽

Plasma Viscosity ◽

Inhibitor Complex ◽

Vein Occlusion ◽

Crossed Immunoelectrophoresis ◽

Α2 Macroglobulin ◽

Plasmin Inhibitor ◽

Soluble Complexes

A defibrination agent (Defibrase®) has been administered to 8 patients with retinal vein occlusion. Defibrase has been infused sub-cutaneously at a dose of 0.5 B. U./kg/day for 5 days followed by 1 to 2 B.U./kg twice a week, for 2 other weeks, so that fibrinogen level was maintained below 100 mg/100 ml. The tests performed were the following : fibrinogen, FDP, soluble complexes, plasminogen, α2 macroglobulin, antithrombin III, α2-plasmin inhibitor (amidolytic and Laurell methods), blood and plasma viscosity. They have been done before treatment and repeated daily for 5 days and then on the 8th, 11th, 14th and 21st day.A decrease in fibrinogen, viscosity, plasminogen and an increase in FDP and soluble complexes have been observed, as already described. The results of the α2- plasmin inhibitor shows a decrease of about 50 % that is slightly more pronounced by the Laurell method than the amidolytic method. The plasmin-α2 plasmin inhibitor complex detected by crossed immunoelectrophoresis is present in various amounts.

Download Full-text